New drug inclisiran aims to lower cholesterol better in chinese heart patients

NCT ID NCT06941792

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether inclisiran, a newer cholesterol-lowering drug, works better than standard treatments for Chinese patients with coronary heart disease. About 1,590 adults whose cholesterol is still high despite statins will receive either inclisiran or usual care. The main goal is to see how much LDL cholesterol drops after one year and how many patients reach their target levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inclisiran
What this could lead to: If it works, this could offer a more effective way to control cholesterol and reduce heart disease risk in Chinese patients.
What could go wrong: This is a phase 4 trial, so inclisiran is already approved; the main question is how it performs in real-world Chinese patients. It may not show a big advantage over standard care, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY HEART DISEASE

Contacts and locations

Locations

Novartis Investigated Site

Taiyuan, Shanxi, 030000, China
Novartis Investigative Site

Anqing, Anhui, 246003, China
Novartis Investigative Site

Beijing, Beijing Municipality, 102218, China
Novartis Investigative Site

Chongqing, Chongqing Municipality, 400010, China
Novartis Investigative Site

Longyan, Fujian, 364099, China
Novartis Investigative Site

Jiamusi, Heilongjiang, 154002, China
Novartis Investigative Site

Zhengzhou, Henan, 451400, China
Novartis Investigative Site

Baotou, Inner Mongolia, 014010, China
Novartis Investigative Site

Shenyang, Liaoning, 110016, China
Novartis Investigative Site

Shenyang, Liaoning, 121100, China
Novartis Investigative Site

Jining, Shandong, 272000, China
Novartis Investigative Site

Weifang, Shandong, 261000, China
Novartis Investigative Site

Shanghai, Shanghai Municipality, 200065, China
Novartis Investigative Site

Chengdu, Sichuan, 610031, China
Novartis Investigative Site

Ürümqi, Xinjiang Uygur Autonomous Region, 830054, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310007, China
Novartis Investigative Site

Jinhua, Zhejiang, 321000, China
Novartis Investigative Site

Ningbo, Zhejiang, 315000, China
Novartis Investigative Site

Wenzhou, Zhejiang, 325000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.